Company Profile
MeiraGTx Stock Price, News & Catalysts
- Ticker:
- MGTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom with U
Stock performance
13.77 USD (+1.85%)
Close
Last updated: August 17, 2026
856M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, MGTX closed up 1.85% at $13.77. No new same-company headline was identified in the current news window.
Company overview
Genetic Medicines Company
MeiraGTx develops and manufactures gene therapies for inherited retinal disease, salivary-gland disorders, and other conditions. Its vertically integrated model spans vector design, clinical development, and commercial manufacturing.
Bota-Vec
Botaretigene sparoparvovec is an AAV gene therapy for X-linked retinitis pigmentosa caused by RPGR mutations. MeiraGTx acquired global rights after completion of the Phase 3 LUMEOS study.
AAV2-hAQP1
AAV2-hAQP1 delivers the aquaporin-1 water-channel gene to salivary glands as a treatment for radiation-induced xerostomia. The program has received FDA Breakthrough Therapy designation.
Riboswitch Platform
MeiraGTx's Riboswitch technology is designed to regulate therapeutic-protein production with an oral small molecule after gene delivery. Initial programs include metabolic disease and neuropathic pain.
Manufacturing Infrastructure
The company operates gene-therapy manufacturing and quality-control facilities intended to support regulatory filings and potential commercial launches.
Future catalysts
- Global regulatory filings for bota-vec in X-linked retinitis pigmentosa during 2026.
- Potential commercial launch of bota-vec in 2027, subject to approval.
- Potential BLA submission for AAV2-hAQP1 in radiation-induced xerostomia in mid-2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of MeiraGTx (MGTX)?
MeiraGTx (MGTX) most recently closed at 13.77 USD, a +1.85% move versus the previous session.
What is the market cap of MeiraGTx (MGTX)?
MeiraGTx currently has a market capitalization of 856M USD on BioPharmSignal.
What does MeiraGTx do?
Genetic Medicines Company MeiraGTx develops and manufactures gene therapies for inherited retinal disease, salivary-gland disorders, and other conditions. Its vertically integrated model spans vector design, clinical development, and commercial manufacturing. Bota-Vec Botaretigene sparoparvovec is an AAV gene therapy for X-linked retinitis pigmentosa caused...
On which exchange is MGTX stock listed?
MeiraGTx (MGTX) is associated with NASDAQ, United Kingdom with U, Biopharma.
What is Genetic?
Genetic Medicines Company MeiraGTx develops and manufactures gene therapies for inherited retinal disease, salivary-gland disorders, and other conditions.
Which conditions is MeiraGTx targeting with Genetic?
MeiraGTx is associated with metabolic disease, genetic disease based on its company overview and current catalyst commentary.
How does MeiraGTx describe recent progress with Genetic?
Global regulatory filings for bota-vec in X-linked retinitis pigmentosa during 2026. Potential commercial launch of bota-vec in 2027, subject to approval. Potential BLA submission for AAV2-hAQP1 in radiation-induced xerostomia in mid-2027.
What is Medicines?
Genetic Medicines Company MeiraGTx develops and manufactures gene therapies for inherited retinal disease, salivary-gland disorders, and other conditions.